AzTrials
AzTrials

To Determine the Optimal Doses of Adrenaline in Preventing Blood Loos in Participants Undergoing Supraclavicular Flap SurgeryPhase 1NCT05670808

"The Effect Of Subcutaneous Epinephrine Dosage On Blood Loss In Surgical Incision"

A Phase 1 study testing Epinephrine injection in people with To Determine the Optimal Doses of Adrenaline in Preventing Blood Loos in Participants Undergoing Supraclavicular Flap Surgery, run by Dow University of Health Sciences.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Several studies have attempted to calculate the ideal epinephrine concentration for vasoconstriction, however there has been little consensus. These experiments were carried out on animals, and the degree of vasoconstriction was measured using a variety of methods. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
Epinephrine injection
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
90 participants
Where
No sites listed yet
Study dates
1 Feb 2023to 30 Jul 2023
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Age≥ 18 years
  • Patients who are undergoing supraclavicular flap surgery
  • Patients wishing to be a part of study.
  • Either gender

Who cannot join

  • • Participants with cardio vascular diseases.
  • Participants with collagen vascular diseases
  • Participant who are on non-steroidal anti-inflammatory drugs, anticoagulants, or aspirin. .

About this study

Several studies have attempted to calculate the ideal epinephrine concentration for vasoconstriction, however there has been little consensus. These experiments were carried out on animals, and the degree of vasoconstriction was measured using a variety of methods. Animal studies aren't always reliable since animal capillary density differs from human capillary density. Furthermore, because the density of capillaries in the head and neck is 30 to 40% higher than in other parts of the body, previous studies may not adequately reflect the ideal epinephrine concentration for this highly vascular location. As a result of this study, clinicians will be able to determine the appropriate dose of epinephrine to control intraoperative bleeding. This study aims to determine the effect of different doses of epinephrine on volume of bleeding in surgical incisions in participants undergoing supraclavicular flap surgery.

Read the detailed description

INTRODUCTION The supraclavicular fasciocutaneous flap has recently been described for the repair of pharyngeal, oral cavity, parotid, lateral skull base, and cutaneous defects, among other head and neck deformities.The usage of this flap has been demonstrated to be well tolerated by patients, with low donor site morbidity and good recipient site viability.The supraclavicular flap is fairly thick, has a colour and texture similar to the head and neck area, and has a clear and consistent blood supply. The fap is easy to prepare, and the surgery takes only a few minutes. With the advancement of plastic surgery, the use of the supraclavicular flap is gaining popularity.

Bleeding is one of the most common problems in plastic surgery, and epinephrine injections have long been used to reduce blood loss. Bleeding during surgery can lead to issues such as a drop in haemoglobin, which may necessitate a blood transfusion. Perioperative blood transfusion was found to have an immunosuppressive impact, increasing the risk of infection after surgery. Blood transfusion or mandibular plate rebuilding was similarly associated with severe tissue ablation and a major surgical defect.

Various approaches, such as controlled hypotensive state surgery and infiltration of vasoconstrictive medicines, have been utilized to reduce the quantity of bleeding during the operation. All of these techniques have their own set of difficulties and adverse effects. Vasoconstrictive medications, particularly subcutaneous epinephrine, are now widely utilized to limit bleeding in cosmetic and reconstructive procedures.Due of its potential cardiac and local toxic consequences, ephinephrine has limitations. Arrhythmias, tachycardia, hypertension, and pulmonary edema are all cardiac toxicities that are exacerbated by the administration of hydrocarbon anaesthetics. Delay in healing, lower wound tensile strength, skin necrosis, and higher infection rates are all local toxic consequences.

Because these problems are dose-related, determining the minimum ephinephrine concentration required for adequate hemostasis during head and neck surgery involving supraclavicular flap would vastly improve its margin of safety. To the best of our knowledge, no research has been done on the effect of epinephrine on bleeding in participants undergoing supraventricular flap surgery. However, a study that looked at the impact of varying dosages of epinephrine on the level of vasoconstriction revealed that there were no significant differences in blood flow reduction between epinephrine concentrations of 1:100,000, 1:200,000, and 1:400,000. Epinephrine 1:800,000, on the other hand, caused substantially less vasoconstriction. To achieve optimal initial hemostasis while avoiding potential adverse effects, we recommend administering an epinephrine concentration of 1:200,000 or 1:400,000.

Objective:

  1. To determine the effect of different doses of epinephrine on volume of bleeding in surgical incisions in participants undergoing supraclavicular flap surgery
  2. To determine the optimal doses of adrenaline in preventing blood loos in participants undergoing supraclavicular flap surgery

Rationale:

Several studies have attempted to calculate the ideal epinephrine concentration for vasoconstriction, however there has been little consensus. 5-9 These experiments were carried out on animals, and the degree of vasoconstriction was measured using a variety of methods. Animal studies aren't always reliable since animal capillary density differs from human capillary density. Furthermore, because the density of capillaries in the head and neck is 30 to 40% higher than in other parts of the body, previous studies may not adequately reflect the ideal epinephrine concentration for this highly vascular location.

As a result of this study, clinicians will be able to determine the appropriate dose of epinephrine to control intraoperative bleeding.

Operational Definition:

Measurement of bleeding The amount Bleeding will be measured by two methods

  1. By Volumetric method in suction bottle: Intraoperative blood loss will be measured by direct measuring the volume of blood in the suction bottle
  2. By Gauze pieces. If gauze is used, it will be weighted before use and again after use when it has been soaked with blood, with the excess weight of the saturated gauze being quantified in milliliters of blood loss. All gauzes of same weight will be selected and digital weighting machine will be used.

Safety of different dosage will be monitor by

1.Heart Rate: Heart rate of patients will be monitor at base line and 5 min of administering of Adrenaline 2 Blood Pressure: BP will of patients will be monitor at base line and 5 min of administering of Adrenaline

MATERIAL AND METHODS:

STUDYDESIGN: Single blinded Randomized control trial

STUDYARMS:

Epinephrine 1:200,000: In this group participants will receive the epinephrine concentration of 1:200,000 in normal saline Epinephrine 1:400,000: In this group participants will receive the epinephrine concentration of 1:400,000 in normal saline Placebo: In this group participants will receive only 10 ml of normal saline (control group) SETTING: Study will be conducted in the plastic surgery department of DUHS

DURATION OF STUDY: Six months after ERC approval SAMPLE SIZE: Once ERC approval is received, sample size will be estimated after conducting a pilot study.

SAMPLING TECHNIQUE: Non-Probability consecutive sampling SELECTION CRITERIA

Inclusion criteria:

  • Age≥ 18 years
  • Patients who are undergoing supraclavicular flap surgery
  • Patients wishing to be a part of study.
  • Either gender

Exclusion criteria:

  • Participants with cardio vascular diseases.
  • Participants with collagen vascular diseases
  • Participant who are on non-steroidal anti-inflammatory drugs, anticoagulants, or aspirin. .

DATA COLLECTION PROCEDURE:

Study will be commenced after CPSP and ERC approval. An informed consent will be taken from all the eligible patients. All the eligible patients will randomly be divided into three above mentioned groups. Participants will be randomized using a random number generator in excel. It will be single blinded study, Researcher will know the drug concentration but the participant will not know that what they will get in the study. At the time of enrolment the patient will be informed regarding the all interventional group of the studies and the probabilities of falling in any one treatment group at the time of taking inform consent. In two interventional groups of participants, ten milliliters of epinephrine in normal saline with doses of 1:200,000 and 1:400,000 will be given subcutaneously under the specified flaps before making the incision. Only 10 milliliters of normal saline will be used in the control group. 15 minutes after the injection, incisions will be created, and flaps will be released from the donor area using a dermatome. Bleeding will be measured for 5 minutes by Volumetric method (Intraoperative blood loss will be measured by direct measuring the volume of blood in the suction bottle).

A predesigned questionnaire will be used to gather information about the blood loss and epinephrine concentration. The participant heart rate, rhythm and blood pressure will be closely monitor during the procedure to avoid any adverse event.

DATA ANALYSIS PROCEDURE:

Data will be entered and analyzed using SPSS version 26.0. Mean ±SD or Median (IQR) will be computed for all the quantitative variables like age, height, weight, BMI, duration of surgery, total blood loss and pre and post HB levels, based on the assumptions of normality. Normality will be checked using Shapiro Wilk test for normality. Frequency and percentage will be computed for all the qualitative variables like gender, co-morbid, occupation, BMI categories, indication of supra clavicular flap, site of surgery and requirement of blood .Chi-square test /Fisher exact test will be applied as appropriate to assess significant association between the treatment group co-morbid, occupation and BMI categories and requirement of blood transfusion. One-way ANOVA /Kruskal-Wallis test will be applied as appropriate to assess significant differences in mean Blood loss, duration of surgery, pre and post-surgery Hb levels between the study group. Effect modifiers such as age, BMI category, indication of surgery, site of surgery will be controlled through stratification. Post-stratification Chi-square/Fisher-Exact test will be applied as appropriate. P-value<0.05 will be considered statistically significant.

Being tested
Epinephrine injection
Keywords
Plastic reconstructive surgery, blood loss, epinephrine, supraclavicular flap
Medical subject headings
Hemorrhage

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Epinephrine injectionDrug

    Different doses on epinephrine will be administered to study arms to observe its impact on blood loss

Study groups in NCT05670808
Study groupRoleWhat they receive
Epinephrine 1:200,000ExperimentalIn this group participants will receive the epinephrine concentration of 1:200,000 in normal saline
Receives: Drug: Epinephrine injection
Epinephrine 1:400,000ExperimentalIn this group participants will receive the epinephrine concentration of 1:400,000 in normal saline
Receives: Drug: Epinephrine injection
PlaceboPlacebo comparatorIn this group participants will receive only 10 ml of normal saline (control group)
Receives: Drug: Epinephrine injection

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Blood loss

    Intraoperative blood loss will be measured by direct measuring the volume of blood in the suction bottle

    Measured: 5 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Jan 2023
  2. Study start1 Feb 2023 (estimated)
  3. Primary completion30 Jun 2023 (estimated)
  4. Study completion30 Jul 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Participant
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05670808
Sponsor's protocol ID
erumnaz1
Status last verified
Dec 2022
First submitted
16 Sep 2022
Last updated
4 Jan 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Epinephrine injection in people with To Determine the Optimal Doses of Adrenaline in Preventing Blood Loos in Participants Undergoing Supraclavicular Flap Surgery, run by Dow University of Health Sciences.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Blood loss (time frame: 5 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jan 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in